LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers. In the pre-clinical study, fifty percent of mice in the combination therapy group (n=10) had complete regressions of primary tumors and metastases at regional and distant sites. Nab-paclitaxel plus bevacizumab was shown to inhibit tumor growth by 100%, and reduced the incidence of lymph node and lung metastases by 50% and 87%, respectively. The findings were discussed during an oral presentation (Abstract #3852) on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.
